<DOC>
	<DOCNO>NCT02430077</DOCNO>
	<brief_summary>Lipodystrophies rare disorder characterize selective loss adipose tissue predisposition insulin resistance metabolic complication . Hepatic steatosis common complication patient partial generalized lipodystrophies.Despite aggressive management diabetes hyperlipidemia , hepatic steatosis complication present therapeutic challenge many patient . Due large disease burden , important ass efficacy safety novel therapy hepatic steatosis patient lipodystrophies.There , however , systematic study evaluate various therapeutic intervention reduce hepatic steatosis patient lipodystrophies . A variety drug investigate nonlipodystrophic patient non-alcoholic hepatic steatosis steatohepatitis ( NASH ) non-alcoholic fatty liver disease ( NAFLD ) . Recent data support activation farnesoid X receptor ( FXR , NR1H4 ) , nuclear hormone receptor regulate bile acid , treatment NASH NAFLD . FXR activate transcription several gene particularly atypical nuclear receptor small heterodimer partner ( SHP , NR0B2 ) thus influence triglyceride metabolism within hepatocytes.Both cholic acid ( CA ) chenodeoxycholic acid ( CDCA ) ligands FXR , however , UDCA 7 hydroxy β-epimer CDCA , activate FXR . Obeticholic acid ( OCA ) first-in-class selective FXR agonist approximately 100 fold great FXR-agonistic activity nanomolar range , compare CDCA .It therefore appear FXR modulation offer interest therapeutic possibility treat hepatic steatosis . This study primarily design study efficacy OCA , strong FXR ligand , reduce hepatic triglyceride level patient hepatic steatosis Familial Partial Lipodystrophy ( FPLD ) . If proven effective , may reduce morbidity mortality result sequelae hepatic steatosis patient lipodystrophies .</brief_summary>
	<brief_title>Phase 2 Study Obeticholic Acid Lipodystrophy Patients</brief_title>
	<detailed_description>This study randomize , placebo-controlled cross-over trial . Patients consider eligible study undergo screen evaluation determine eligibility trial . For found eligible , baseline period , continue usual diet lifestyle measure without change medication 1 month order establish baseline state . Three blood sample obtain period Clinical Translational Research Center . Following baseline period , patient receive obeticholic acid ( OCA ) identical placebo dose 25 mg/day period 4 month receive treatment ( OCA placebo ) 4 month . There wash-out period 4 month in-between two study period . Patients educate maintain usual physical activity diet study . The subject admit Clinical Translational Research Center baseline evaluation ( begin two study period ) , end four month study period .</detailed_description>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Lipodystrophy , Familial Partial</mesh_term>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<criteria>1 . Patients familial partial lipodystrophy Dunnigan variety heterozygous diseasecausing missense mutation lamin A/C ( LMNA ) gene . 2 . Hepatic steatosis ( &gt; 5.6 % hepatic triglyceride content ) demonstrate 1H magnetic resonance spectroscopy . 3 . Age 1870 year . 4 . Alcohol intake less 20 g per day females 30 g per day male . 5 . Participants partner sex , must use medicallyacceptable birth control ( contraceptive ) study . Medicallyacceptable method contraception include : ( 1 ) surgical sterilization , hysterectomy , tubal ligation vasectomy . ( 2 ) approve hormonal contraceptive , birth control pill , patch ring ; DepoProvera , Implanon . ( 3 ) barrier method , condom , cervical cap diaphragm use spermicide . ( 4 ) intrauterine device ( IUD ) . 1 . Laboratory histologic finding highly suggestive liver disease due cause nonalcoholic steatohepatitis , chronic viral hepatitis , autoimmune hepatitis , primary biliary cirrhosis , biliary obstruction genetic liver diseases Wilson 's disease , hemochromatosis alpha1antitrypsin deficiency . 2 . Treatment drug associate steatohepatitis , e.g. , corticosteroid , high dose estrogen , methotrexate , amiodarone , tamoxifen , valproic acid , sulfasalazine , oxacillin 2 week 6 month prior study . 3 . Decompensated liver disease evidence clinical feature hepatic failure ( variceal bleeding , ascites , hepatic encephalopathy etc . ) laboratory investigation ( prolonged prothrombin time INR &gt; 1.3 , hypoalbuminemia serum albumin le 3.0 g/dL , direct bilirubin &gt; 1.3 mg/dL , presence esophageal varix etc . ) 4 . Evidence hepatocellular carcinoma : alphafetoprotein level great 200 ng/ml and/or liver mass image study suggestive liver cancer . 5 . Use drug potentially decrease hepatic steatosis previous 3 month ; ursodeoxycholic acid , thiazolidinediones , highdose vitamin E , betaine , acetylcysteine choline . 6 . Significant systemic major illness liver disease , congestive heart failure , cerebrovascular disease , respiratory failure , renal failure ( serum creatinine &gt; 2 mg/dL ) , acute pancreatitis , organ transplantation , serious psychiatric disease , malignancy , could interfere trial adequate follow . 7 . Acute medical illness preclude participation study . 8 . Known HIVinfected patient . 9 . Current substance abuse . 10 . Pregnant lactate woman . 11 . Hematocrit le 30 % . 12 . History weight loss past 3 month . 13 . Patients bile acid binding resin , cholestyramine , colestipol colesevelam . 14 . Hypersensitivity intolerance OCA component formulation . 15 . Failure give inform consent 16 .Previous clinical diagnosis diabetes mellitus fast blood glucose ≥ 126 mg/dL hemoglobin A1c ≥ 6.5 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hepatic Steatosis</keyword>
</DOC>